Cabozantinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Cabozantinib comprises 365 peer-reviewed publications across 15 journals, 19 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Prostatic Neoplasms, and Carcinoma, Non-Small-Cell Lung. Most recent publication: Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma., J Immunother Cancer, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
    Zehir A, Benayed R, Shah RH, et al. · Nat Med · 2017
    PubMed: PMID 28481359 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
    Seymour L, Bogaerts J, Perrone A, et al. · Lancet Oncol · 2017
    PubMed: PMID 28271869 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T, O'Donnell PH, Massard C, et al. · JAMA Oncol · 2017
    PubMed: PMID 28817753 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. Bladder cancer.
    Kamat AM, Hahn NM, Efstathiou JA, et al. · Lancet · 2017
    PubMed: PMID 27345655 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  5. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Drilon A, Rekhtman N, Arcila M, et al. · Lancet Oncol · 2017
    PubMed: PMID 27825636 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  6. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
    Choueiri TK, McDermott DF, Merchan J, et al. · Lancet Oncol · 2023
    PubMed: PMID 37011650 · NCT03634540 · Carcinoma, Renal Cell
  7. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK, Escudier B, Powles T, et al. · Lancet Oncol · 2017
    PubMed: PMID 27279544 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  8. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
    Apolo AB, Nadal R, Tomita Y, et al. · Lancet Oncol · 2020
    PubMed: PMID 32645282 · NCT01688999 · Kidney Neoplasms

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01522443
COMET-2
Prostatic NeoplasmsPain Response at Week 6 Confirmed at Week 12, Week 12 Reported
Pain response was measured at Week 6 and Week 12 by self-reports of subjects
Cabozantinib15 percentage of responders
Mitoxantrone/Prednisone17 percentage of responders
NCT01605227
COMET-1
Prostatic NeoplasmsOverall Survival (OS)
OS was measured from the time of randomization until 614 events, approximately 24 months after study start
Cabozantinib11.0 months
Prednisone9.8 months
NCT01865747
METEOR
Carcinoma, Renal CellProgression-free Survival (PFS)
PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.
Cabozantinib (XL184)7.4 months
Everolimus (Afinitor)3.8 months
NCT01908426
CELESTIAL
Carcinoma, HepatocellularOverall Survival (OS)
Up to 45 months
Cabozantinib (XL184)10.2 months
Placebo8.0 months
NCT03141177
CheckMate 9ER
Carcinoma, Renal CellProgression Free Survival (PFS)
From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)
Treatment A16.59 Months
Treatment C8.31 Months
NCT03375320Neuroendocrine TumorsProgression-free Survival (PFS)
36 months
Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])8.4 months
Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])13.8 months
Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])3.9 months
Arm IIb (Placebo, Pancreatic NET Cohort [pNET])4.4 months
NCT03690388Thyroid NeoplasmsObjective Response Rate (ORR)
Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
Cabozantinib15 percentage of participants
Placebo0 percentage of participants
NCT03690388Thyroid NeoplasmsProgression Free Survival (PFS)
Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
CabozantinibNA months
Placebo1.9 months
NCT03729245Carcinoma, Renal CellObjective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC
Approximately 32 months
Combination of Bempegaldesleukin + Nivolumab73 Participants
Combination of Bempegaldesleukin + Nivolumab59 Participants
Sunitinib or Cabozantinib109 Participants
Sunitinib or Cabozantinib79 Participants
NCT03729245Carcinoma, Renal CellOverall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC
Approximately 32 months
Combination of Bempegaldesleukin + Nivolumab29 months
Combination of Bempegaldesleukin + NivolumabNA months
Sunitinib or CabozantinibNA months
Sunitinib or CabozantinibNA months
NCT03755791
COSMIC-312
Carcinoma, HepatocellularOverall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population
From the date of first participant randomization up to 36 months
Control Arm: Sorafenib15.51 months
Experimental Arm: Cabozantinib + Atezolizumab16.46 months
NCT03755791
COSMIC-312
Carcinoma, HepatocellularProgression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population
From the date of first participant randomization up to 28 months
Control Arm: Sorafenib4.21 months
Experimental Arm: Cabozantinib + Atezolizumab6.80 months
NCT03937219
COSMIC-313
Carcinoma, Renal CellDuration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)
Up to 32 months
Cabozantinib + Nivolumab + IpilimumabNA months
Placebo + Nivolumab + Ipilimumab11.30 months
NCT04211337
LIBRETTO-531
Carcinoma, MedullaryProgression Free Survival (PFS) by Blinded Independent Central Review (BICR)
Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months
Cabozantinib or Vandetanib (TRT B)16.76 Months
Selpercatinib (TRT A)NA Months
NCT04338269
CONTACT-03
Carcinoma, Renal CellOverall Survival (OS)
From randomization to death due to any cause (up to 2 years 5 months).
Atezolizumab + Cabozantinib25.72 months
Cabozantinib (Control)NA months
NCT04338269
CONTACT-03
Carcinoma, Renal CellProgression Free Survival (PFS) as Assessed by an Independent Review Facility (IRF) (IRF-PFS) According to RECIST v1.1
From randomization to the first occurrence of PD according to RECIST v1.1, or death from any cause, whichever occurred first (up to 2 years 5 months)
Atezolizumab + Cabozantinib10.55 months
Cabozantinib (Control)10.81 months
NCT04446117
CONTACT-02
Prostatic NeoplasmsDuration of Overall Survival (OS)
Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)
Control Arm: Second NHT14.98 months
Experimental Arm: Cabozantinib and Atezolizumab14.78 months
NCT04446117
CONTACT-02
Prostatic NeoplasmsDuration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)
Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)
Control Arm: Second NHT4.17 months
Experimental Arm: Cabozantinib and Atezolizumab6.34 months
NCT04471428
CONTACT-01
Carcinoma, Non-Small-Cell LungOverall Survival (OS)
Up to approximately 24 months
Atezolizumab + Cabozantinib10.7 months
Docetaxel Monotherapy10.5 months

Publications by year

1983–2026: 365 publications.

1983
2
1986
1
1988
1
1989
4
1990
2
1991
1
1992
1
1993
1
1995
1
1996
1
1997
2
1998
3
1999
2
2000
1
2001
3
2002
2
2003
2
2004
2
2005
5
2006
6
2007
13
2008
12
2009
12
2010
9
2011
15
2012
12
2013
11
2014
14
2015
21
2016
15
2017
21
2018
9
2019
11
2020
18
2021
27
2022
41
2023
23
2024
18
2025
11
2026
9

Publications by indication

Carcinoma, Renal Cell (87)

  • Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
    J Immunother Cancer · 2026 · PMID 41617395 · NCT03141177
  • Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
    Eur J Cancer · 2026 · PMID 41946178 · NCT03967522
  • Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
    Oncol Ther · 2026 · PMID 41239083 · NCT03141177
  • COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.
    J Clin Oncol · 2025 · PMID 39965176 · NCT03170960
  • Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
    Lancet Oncol · 2025 · PMID 39756444 · NCT03634540

Carcinoma, Hepatocellular (41)

  • Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
    Lancet Gastroenterol Hepatol · 2024 · PMID 38364832 · NCT03755791
  • Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.
    Immunotherapy · 2023 · PMID 36852452 · NCT01658878
  • Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
    Genome Med · 2023 · PMID 37723590 · NCT03299946
  • Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    J Clin Oncol · 2023 · PMID 36512738 · NCT01658878
  • Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Cochrane Database Syst Rev · 2023 · PMID 37185961 · NCT00940225

Prostatic Neoplasms (30)

  • Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Semin Cancer Biol · 2025 · PMID 39863139 · NCT03878524
  • Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
    Lancet Oncol · 2025 · PMID 40523369 · NCT04446117
  • Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease.
    Clin Kidney J · 2024 · PMID 28396734 · NCT05265988
  • An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment.
    Value Health · 2022 · PMID 35779938 · NCT01522443
  • Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
    Qual Life Res · 2022 · PMID 34420143 · NCT01522443

Carcinoma, Non-Small-Cell Lung (26)

  • CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
    J Clin Oncol · 2024 · PMID 38552197 · NCT04471428
  • Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
    Front Oncol · 2023 · PMID 30915273 · NCT01866410
  • Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
    Thorac Cancer · 2022 · PMID 34409776 · NCT04471428
  • A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
    Eur J Cancer · 2017 · PMID 28755607 · NCT04131543
  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Lancet Oncol · 2017 · PMID 27825636 · NCT04131543

Urinary Bladder Neoplasms (20)

  • Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
    Clin Genitourin Cancer · 2021 · PMID 34006499 · NCT03824691
  • Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?
    Transl Androl Urol · 2020 · PMID 28078238 · NCT03824691
  • Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Eur Urol · 2018 · PMID 27726966 · NCT03824691
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
    Nat Med · 2017 · PMID 28481359 · NCT03824691
  • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
    Lancet Oncol · 2017 · PMID 28271869 · NCT03824691

Central Nervous System Neoplasms (14)

  • High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.
    Int J Radiat Oncol Biol Phys · 2020 · PMID 31786276 · NCT05425004
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
    Neuro Oncol · 2019 · PMID 29016998 · NCT05425004
  • Advances in meningioma genetics: novel therapeutic opportunities.
    Nat Rev Neurol · 2019 · PMID 29302064 · NCT05425004
  • Economics of Malignant Gliomas: A Critical Review.
    J Oncol Pract · 2018 · PMID 25466707 · NCT05425004
  • A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
    J Neurooncol · 2017 · PMID 27311730 · NCT05425004

Publications by journal

  • J Clin Oncol33 papers
  • Lancet Oncol21 papers
  • N Engl J Med15 papers
  • J Urol15 papers
  • Clin Cancer Res12 papers
  • Eur J Cancer11 papers
  • Eur Urol11 papers
  • Oncologist9 papers
  • Nat Med8 papers
  • Ann Oncol8 papers

Trial-results highlights

For prostatic neoplasms, the NCT01522443 (COMET-2) study evaluated pain response. At Week 12, the Cabozantinib arm reported 15 percentage of responders, while the Mitoxantrone/Prednisone arm reported 17 percentage of responders. In the NCT01605227 (COMET-1) study, median overall survival was 11.0 months for the Cabozantinib arm and 9.8 months for the Prednisone arm.

In renal cell carcinoma, the NCT01865747 (METEOR) study found a progression-free survival of 7.4 months for the Cabozantinib (XL184) arm, compared to 3.8 months for the Everolimus (Afinitor) arm. Another study, NCT03141177 (CheckMate 9ER), reported a median progression-free survival of 16.59 Months for Treatment A and 8.31 Months for Treatment C.

For hepatocellular carcinoma, the NCT01908426 (CELESTIAL) study reported a median overall survival of 10.2 months for the Cabozantinib (XL184) arm and 8.0 months for the Placebo arm. In neuroendocrine tumors, the NCT03375320 study observed median progression-free survival values:

  • Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]): 8.4 months
  • Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]): 13.8 months
  • Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]): 3.9 months
  • Arm IIb (Placebo, Pancreatic NET Cohort [pNET]): 4.4 months
For thyroid neoplasms, the NCT03690388 study reported an objective response rate of 15 percentage of participants for the Cabozantinib arm, versus 0 percentage of participants for the Placebo arm. The same study also reported a median progression-free survival of 1.9 months for the Placebo arm.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Cabozantinib publications (365)

2026 (9 papers)

  1. Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
    Viray H, M Mantia C, Jegede OA, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41617395 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  2. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  3. Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
    Strosberg JR, Zemla T, Geyer S, et al. · Endocr Relat Cancer · 2026 · Derived
    PubMed: PMID 41524552 · NCT03375320 · Neuroendocrine Tumors
  4. Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
    Negrier S, Mourey L, Dalban C, et al. · Eur J Cancer · 2026 · Derived
    PubMed: PMID 41946178 · NCT03967522 (CABRAMET) · Carcinoma, Renal Cell
  5. Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.
    Monga V, Okuno S, Van Tine B, et al. · Lancet Oncol · 2026 · Derived
    PubMed: PMID 41554272 · NCT04200443 · Sarcoma
  6. Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).
    Mandl A, Chen R, Das S, et al. · Oncologist · 2026 · Derived
    PubMed: PMID 41968073 · NCT04079712 · Neuroendocrine Tumors
  7. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
    Jiao XD, Qin BD, Wang Z, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 36910668 · NCT03239015 · Neoplasms
  8. Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
    Grimm MO, Karim E, Kapetanakis V, et al. · Oncol Ther · 2026 · Derived
    PubMed: PMID 41239083 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  9. Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study.
    Cives M, Della Vittoria Scarpati G, Clemente O, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41963331 · NCT04893785 (CABOTEM) · Gastro-enteropancreatic neuroendocrine tumor

2025 (11 papers)

  1. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Prostatic Neoplasms
  2. Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5.
    Payakachat N, Gilligan AM, Altman D, et al. · J Geriatr Oncol · 2025 · Derived
    PubMed: PMID 40617171 · NCT04211337 (LIBRETTO-531) · Carcinoma, Medullary
  3. COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.
    Pal SK, Loriot Y, Necchi A, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39965176 · NCT03170960 · Carcinoma, Renal Cell
  4. Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.
    Konda B, Sherman EJ, Massarelli E, et al. · J Clin Endocrinol Metab · 2025 · Derived
    PubMed: PMID 39133806 · NCT03914300 · Thyroid Neoplasms
  5. Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.
    Guo Z, Liu J, Zhang X, et al. · Endocrine · 2025 · Derived
    PubMed: PMID 40304938 · NCT06482086
  6. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
    Choueiri TK, Merchan JR, Figlin R, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39756444 · NCT03634540 · Carcinoma, Renal Cell
  7. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
    Chan JA, Geyer S, Zemla T, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39282913 · NCT03375320 · Neuroendocrine Tumors
  8. Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma.
    Cella D, Motzer RJ, Suarez C, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39452894 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  9. Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial.
    Bilen MA, Vo BT, Liu Y, et al. · Res Sq · 2025 · Derived
    PubMed: PMID 39149474 · NCT04022343 · Carcinoma, Renal Cell
  10. Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
    Beckermann KE, Shah NJ, Campbell MT, et al. · Oncologist · 2025 · Derived
    PubMed: PMID 40549043 · NCT04300140 · Carcinoma, Renal Cell
  11. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
    Agarwal N, Azad AA, Carles J, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40523369 · NCT04446117 (CONTACT-02) · Prostatic Neoplasms

2024 (18 papers)

  1. Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease.
    Vega A, Abad S, Macías N, et al. · Clin Kidney J · 2024 · Trial result
    PubMed: PMID 28396734 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens.
    Tan Z, Völler S, Yin A, et al. · Clin Pharmacokinet · 2024 · Trial result
    PubMed: PMID 38874883 · NCT07077161 (SKIPPY 2) · Carcinoma, Renal Cell
  3. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
    Yau T, Kaseb A, Cheng AL, et al. · Lancet Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38364832 · NCT03755791 (COSMIC-312) · Carcinoma, Hepatocellular
  4. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
    Tannir NM, Formiga MN, Penkov K, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38838287 · NCT03729245 · Carcinoma, Renal Cell
  5. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
    Powles T, Burotto M, Escudier B, et al. · ESMO Open · 2024 · Derived
    PubMed: PMID 38642472 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  6. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
    Neal J, Pavlakis N, Kim SW, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38552197 · NCT04471428 (CONTACT-01) · Carcinoma, Non-Small-Cell Lung
  7. Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021).
    Li D, Loriot Y, Burgoyne AM, et al. · EClinicalMedicine · 2024 · Derived
    PubMed: PMID 38204489 · NCT03170960 · Carcinoma, Renal Cell
  8. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial.
    Jimenez C, Habra MA, Campbell MT, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38608693 · NCT02302833 · Paraganglioma
  9. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  10. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
    Ebrahimi H, Dizman N, Meza L, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38942995 · NCT05122546 · Carcinoma, Renal Cell
  11. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
    Dayyani F, Chao J, Lee FC, et al. · Oncologist · 2024 · Derived
    PubMed: PMID 38823034 · NCT04164979
  12. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.
    Dayyani F, Balangue J, Valerin J, et al. · Clin Colorectal Cancer · 2024 · Derived
    PubMed: PMID 38103947 · NCT04868773 · Neoplasm Metastasis
  13. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL, Ryoo BY, Mo F, et al. · J Hepatol · 2024 · Derived
    PubMed: PMID 38570034 · NCT04588051
  14. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J, Krajewska J, Hernando J, et al. · Thyroid · 2024 · Derived
    PubMed: PMID 38062732 · NCT03690388 · Thyroid Neoplasms
  15. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
    Campbell MT, Balderrama-Brondani V, Jimenez C, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38608694 · NCT03370718 · Adrenal Cortex Neoplasms
  16. Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.
    Brown J, Harrow B, Marciniak A, et al. · Drugs Real World Outcomes · 2024 · Derived
    PubMed: PMID 38265633 · NCT04637204 · Carcinoma, Renal Cell
  17. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
    Barata P, Tangen C, Plets M, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39255440 · NCT02761057 · Carcinoma, Renal Cell
  18. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
    Apolo AB, Girardi DM, Niglio SA, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38954785 · NCT02496208 · Carcinoma, Renal Cell

2023 (23 papers)

  1. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
    Choueiri TK, McDermott DF, Merchan J, et al. · Lancet Oncol · 2023 · Trial result
    PubMed: PMID 37011650 · NCT03634540 · Carcinoma, Renal Cell
  2. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.
    Zhou X, Cao J, Topatana W, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 36852452 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  3. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
    Zhang S, Yuan L, Danilova L, et al. · Genome Med · 2023 · Derived
    PubMed: PMID 37723590 · NCT03299946 · Carcinoma, Hepatocellular
  4. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  5. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    Yau T, Zagonel V, Santoro A, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36512738 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  6. Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.
    Weijers JAM, de Bitter TJJ, Verhaegh GW, et al. · Oral Oncol · 2023 · Derived
    PubMed: PMID 37939426 · NCT03729297 (Cabo ASAP) · Carcinoma, Adenoid Cystic
  7. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
    Tran BD, Li J, Ly N, et al. · Cancer Chemother Pharmacol · 2023 · Derived
    PubMed: PMID 36625894 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  8. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
    Saba NF, Steuer CE, Ekpenyong A, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37012550 · NCT03468218 · Squamous Cell Carcinoma of Head and Neck
  9. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
    Reckamp KL, Frankel PH, Ruel N, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 30915273 · NCT01866410 · Carcinoma, Non-Small-Cell Lung
  10. Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
    Qin BD, Jiao XD, Wang Z, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37155342 · NCT03239015 · Neoplasms
  11. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
    Petersohn S, McGregor B, Klijn SL, et al. · J Comp Eff Res · 2023 · Derived
    PubMed: PMID 37431849 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  12. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
    Pal SK, Albiges L, Tomczak P, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37290461 · NCT04338269 (CONTACT-03) · Carcinoma, Renal Cell
  13. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
    Nakaigawa N, Tomita Y, Tamada S, et al. · Int J Clin Oncol · 2023 · Derived
    PubMed: PMID 36595123 · NCT03339219
  14. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
    Motzer RJ, Schmidinger M, Eto M, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36752726 · NCT04586231 · Carcinoma, Renal Cell
  15. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
    Li H, Sahu KK, Brundage J, et al. · Oncologist · 2023 · Derived
    PubMed: PMID 36952231 · NCT03200587 · Carcinoma, Renal Cell
  16. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
    Kessler ER, Callihan E, Hu J, et al. · Cancer Res Commun · 2023 · Derived
    PubMed: PMID 37377613 · NCT03149822 · Carcinoma, Renal Cell
  17. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
    Hadoux J, Elisei R, Brose MS, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37870969 · NCT04211337 (LIBRETTO-531) · Carcinoma, Medullary
  18. RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment.
    Gong AJ, Ruchalski K, Kim HJ, et al. · Radiol Imaging Cancer · 2023 · Derived
    PubMed: PMID 37656041 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  19. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  20. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37185961 · NCT00940225 · Carcinoma, Hepatocellular
  21. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
    Corti F, Brizzi MP, Amoroso V, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 37752423 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  22. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Choueiri TK, Powles T, Albiges L, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37163623 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  23. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37146227 · NCT02761057 · Carcinoma, Renal Cell

2022 (41 papers)

  1. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
    Yau T, Kang YK, Kim TY, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 33001135 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  2. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
    Yang Y, Psutka SP, Parikh AB, et al. · Cancer Med · 2022 · Derived
    PubMed: PMID 35304832 · NCT03793166 · Carcinoma, Renal Cell
  3. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
    Xing P, Wang M, Zhao J, et al. · Thorac Cancer · 2022 · Derived
    PubMed: PMID 34409776 · NCT04471428 (CONTACT-01) · Carcinoma, Non-Small-Cell Lung
  4. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.
    Wirth LJ, Brose MS, Elisei R, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35969032 · NCT04211337 (LIBRETTO-531) · Carcinoma, Medullary
  5. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT, Collier KA, Tallman D, et al. · Genome Med · 2022 · Derived
    PubMed: PMID 34016182 · NCT01738438 · Neoplasm Metastasis
  6. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan.
    Vaziri H, Turshudzhyan A, Vecchio E, et al. · J Clin Gastroenterol · 2022 · Derived
    PubMed: PMID 35470301 · NCT03816345 · Hematologic Neoplasms
  7. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
    van Boxtel W, Uijen MJM, Krens SD, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 34920917 · NCT03729297 (Cabo ASAP) · Carcinoma, Adenoid Cystic
  8. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  9. An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment.
    Thanarajasingam G, Basch E, Mead-Harvey C, et al. · Value Health · 2022 · Derived
    PubMed: PMID 35779938 · NCT01522443 (COMET-2) · Prostatic Neoplasms
  10. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
    Tannir NM, Agarwal N, Porta C, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 36048457 · NCT03428217 (CANTATA) · Carcinoma, Renal Cell
  11. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.
    Sové RJ, Verma BK, Wang H, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36323435 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  12. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study).
    Procopio G, Sepe P, Claps M, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 35420628 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  13. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  14. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ, Powles T, Burotto M, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35688173 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  15. The Development of Investigator-Initiated Clinical Trials in Surgical Oncology.
    McDonald HG, Cassim EB, Harper MM, et al. · Surg Oncol Clin N Am · 2022 · Derived
    PubMed: PMID 36410913 · NCT05052723 · Neoplasm Metastasis
  16. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
    Mazza GL, Petersen MM, Ginos B, et al. · Qual Life Res · 2022 · Derived
    PubMed: PMID 34420143 · NCT01522443 (COMET-2) · Prostatic Neoplasms
  17. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges.
    Mar N, Kaakour D, Rezazadeh Kalebasty A, et al. · JCO Oncol Pract · 2022 · Derived
    PubMed: PMID 34550754 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  18. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
    Lheureux S, Matei DE, Konstantinopoulos PA, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35288469 · NCT03367741 · Endometrial Neoplasms
  19. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
    Lee CH, Voss MH, Carlo MI, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35298296 · NCT03635892 · Carcinoma, Renal Cell
  20. Setting a new standard for long-term survival in metastatic kidney cancer.
    Labriola MK, George DJ · Cancer · 2022 · Derived
    PubMed: PMID 35383907 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  21. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
    Kyriazoglou A, Jespers P, Vandecavaye V, et al. · Acta Oncol · 2022 · Derived
    PubMed: PMID 35481400 · NCT02216578 · Gastrointestinal Stromal Tumors
  22. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Kudo M, Matilla A, Santoro A, et al. · J Hepatol · 2022 · Derived
    PubMed: PMID 34051329 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  23. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
    Kelley RK, Rimassa L, Cheng AL, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35798016 · NCT03755791 (COSMIC-312) · Carcinoma, Hepatocellular
  24. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
    Kelley RK, Miksad R, Cicin I, et al. · Br J Cancer · 2022 · Derived
    PubMed: PMID 34621044 · NCT01908426 (CELESTIAL) · Carcinoma, Hepatocellular
  25. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
    Jia J, Howard L, Liu Y, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35171350 · NCT02008383 (CaboMAb) · Colorectal Neoplasms
  26. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
    Ho WJ, Zhu Q, Durham J, et al. · Nat Cancer · 2022 · Derived
    PubMed: PMID 34796337 · NCT03299946 · Carcinoma, Hepatocellular
  27. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
    Hamuro L, Hu Z, Passarell J, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34980597 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  28. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
    Girardi DM, Niglio SA, Mortazavi A, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35031545 · NCT02496208 · Carcinoma, Renal Cell
  29. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
    Freemantle N, Mollon P, Meyer T, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35487183 · NCT01908426 (CELESTIAL) · Carcinoma, Hepatocellular
  30. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
    El-Khoueiry AB, Meyer T, Cheng AL, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 35397508 · NCT01908426 (CELESTIAL) · Carcinoma, Hepatocellular
  31. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
    Denize T, Farah S, Cimadamore A, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34921022 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  32. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D, Motzer RJ, Suarez C, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35032437 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  33. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
    Capdevila J, Klochikhin A, Leboulleux S, et al. · Thyroid · 2022 · Derived
    PubMed: PMID 35403447 · NCT01896479 (EXAMINER) · Carcinoma, Medullary
  34. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
    Bade RM, Schehr JL, Emamekhoo H, et al. · Mol Oncol · 2022 · Derived
    PubMed: PMID 33604999 · NCT04071223 · Carcinoma, Renal Cell
  35. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Azhie A, Grant RC, Herman M, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35287469 · NCT04204850 · Carcinoma, Hepatocellular
  36. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
    Apolo AB, Powles T, Escudier B, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 36327527 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  37. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
    Albiges L, Schmidinger M, Taguieva-Pioger N, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 34911359 · NCT03945773 (CaboPoint) · Carcinoma, Renal Cell
  38. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
    Agarwal N, McGregor B, Maughan BL, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35690072 · NCT03170960 · Carcinoma, Renal Cell
  39. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
    Agarwal N, Azad A, Carles J, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35034502 · NCT04446117 (CONTACT-02) · Prostatic Neoplasms
  40. Global burden of primary liver cancer in 2020 and predictions to 2040.
    Rumgay H, Arnold M, Ferlay J, et al. · J Hepatol · 2022 · Background
    PubMed: PMID 36208844 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  41. Immune signature of tumor infiltrating immune cells in renal cancer.
    Geissler K, Fornara P, Lautenschläger C, et al. · Oncoimmunology · 2022 · Background
    PubMed: PMID 25949868 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell

2021 (27 papers)

  1. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
    Strickler JH, Rushing CN, Uronis HE, et al. · Oncologist · 2021 · Trial result
    PubMed: PMID 33469991 · NCT02008383 (CaboMAb) · Colorectal Neoplasms
  2. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
    Xu J, Higgins MJ, Tolaney SM, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 32463152 · NCT01441947 · Neoplasm Metastasis
  3. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges.
    Vatner R, James CD, Sathiaseelan V, et al. · Pediatr Blood Cancer · 2021 · Derived
    PubMed: PMID 32827353 · NCT04220229
  4. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
    Trojan J, Mollon P, Daniele B, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 33822328 · NCT01908426 (CELESTIAL) · Carcinoma, Hepatocellular
  5. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
    Tomita Y, Tatsugami K, Nakaigawa N, et al. · Int J Urol · 2021 · Derived
    PubMed: PMID 32789967 · NCT03339219
  6. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B, Melero I, Wadhawan S, et al. · J Hepatol · 2021 · Derived
    PubMed: PMID 32710922 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  7. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113).
    Ray-Coquard I, Hatcher H, Bompas E, et al. · Int J Gynecol Cancer · 2021 · Derived
    PubMed: PMID 32546554 · NCT01979393 · Neoplasm Metastasis
  8. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
    Powles T, Choueiri TK, Motzer RJ, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 34364385 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  9. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK, Tangen C, Thompson IM, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33592176 · NCT02761057 · Carcinoma, Renal Cell
  10. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
    Pal SK, McGregor B, Suárez C, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34491815 · NCT03170960 · Carcinoma, Renal Cell
  11. Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
    Marandino L, Raggi D, Calareso G, et al. · Clin Genitourin Cancer · 2021 · Derived
    PubMed: PMID 34006499 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  12. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
    Kudo M, Tsuchiya K, Kato N, et al. · J Gastroenterol · 2021 · Derived
    PubMed: PMID 33392749 · NCT03586973
  13. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
    Kelley RK, W Oliver J, Hazra S, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 32491932 · NCT03755791 (COSMIC-312) · Carcinoma, Hepatocellular
  14. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
    Kelley RK, Ryoo BY, Merle P, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 32847838 · NCT01908426 (CELESTIAL) · Carcinoma, Hepatocellular
  15. Medullary thyroid carcinoma.
    Jaber T, Dadu R, Hu MI, et al. · Curr Opin Endocrinol Diabetes Obes · 2021 · Derived
    PubMed: PMID 34292174 · NCT04211337 (LIBRETTO-531) · Carcinoma, Medullary
  16. Gynecological sarcomas: literature review of 2020.
    Hanvic B, Ray-Coquard I · Curr Opin Oncol · 2021 · Derived
    PubMed: PMID 34009140 · NCT01979393 · Neoplasm Metastasis
  17. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
    Fisher MJ, Shih CS, Rhodes SD, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33442015 · NCT02101736 (NF105-CABO) · Neurofibroma, Plexiform
  18. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).
    Dhani NC, Hirte HW, Wang L, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31992589 · NCT01935934 · Carcinoma, Endometrioid
  19. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together.
    D'Alessio A, Cammarota A, Prete MG, et al. · Curr Opin Oncol · 2021 · Derived
    PubMed: PMID 33867478 · NCT04204850 · Carcinoma, Hepatocellular
  20. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
    Coquan E, Brachet PE, Licaj I, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 34563169 · NCT04205799 (CABOCOL-01) · Neoplasm Metastasis
  21. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Choueiri TK, Powles T, Burotto M, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33657295 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  22. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Brose MS, Robinson B, Sherman SI, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34237250 · NCT03690388 · Thyroid Neoplasms
  23. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Basch E, Becker C, Rogak LJ, et al. · Clin Trials · 2021 · Derived
    PubMed: PMID 33258687 · NCT01522443 (COMET-2) · Prostatic Neoplasms
  24. Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
    Bao R, Surriga O, Olson DJ, et al. · Melanoma Res · 2021 · Derived
    PubMed: PMID 33170593 · NCT01835145 · Uveal Melanoma
  25. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
    Apolo AB, Nadal R, Girardi DM, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32915679 · NCT02496208 · Carcinoma, Renal Cell
  26. Abstracts Presented at the 13th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society, October 2-3, 2020.
    Pancreas · 2021 · Derived
    PubMed: PMID 33835977 · NCT04412629
  27. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
    Kroiss M, Megerle F, Kurlbaum M, et al. · J Clin Endocrinol Metab · 2021 · Background
    PubMed: PMID 31900481 · NCT03612232 (CaboACC) · Adrenocortical Carcinoma

2020 (18 papers)

  1. Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?
    Rink M, Shariat SF, Soave A, et al. · Transl Androl Urol · 2020 · Trial result
    PubMed: PMID 28078238 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
    Apolo AB, Nadal R, Tomita Y, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 32645282 · NCT01688999 · Kidney Neoplasms
  3. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
    Yau T, Hsu C, Kim TY, et al. · J Hepatol · 2020 · Derived
    PubMed: PMID 31176752 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  4. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P, Mir O, Kasper B, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 32470848 · NCT02216578 · Gastrointestinal Stromal Tumors
  5. Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.
    Nokihara H, Nishio M, Yamamoto N, et al. · Clin Lung Cancer · 2020 · Derived
    PubMed: PMID 30718102 · NCT01553656 · Neoplasm Metastasis
  6. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
    Leone JP, Duda DG, Hu J, et al. · Breast Cancer Res Treat · 2020 · Derived
    PubMed: PMID 31541381 · NCT02260531 · Brain Neoplasms
  7. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age.
    Kunz PL · Lancet Oncol · 2020 · Derived
    PubMed: PMID 33152282 · NCT03375320 · Neuroendocrine Tumors
  8. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A, Mir O, Mathoulin-Pelissier S, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32078813 · NCT02243605 · Osteosarcoma
  9. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F, Hwang EC, Lam TB, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 33058158 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  10. An update on emerging drugs in osteosarcoma: towards tailored therapies?
    Hattinger CM, Patrizio MP, Magagnoli F, et al. · Expert Opin Emerg Drugs · 2020 · Derived
    PubMed: PMID 31401903 · NCT02243605 · Osteosarcoma
  11. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
    George DJ, Hessel C, Halabi S, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 31399500 · NCT01835158 · Carcinoma, Renal Cell
  12. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
    Flaifel A, Xie W, Braun DA, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31371341 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  13. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC, Scher HI, Bennett AV, et al. · JAMA Oncol · 2020 · Derived
    PubMed: PMID 31556911 · NCT01522443 (COMET-2) · Prostatic Neoplasms
  14. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F, Motzer RJ, Voog E, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 31887537 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  15. Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape.
    Armstrong AE, Brossier NM, Hirbe AC, et al. · Lancet Child Adolesc Health · 2020 · Derived
    PubMed: PMID 32562630 · NCT02101736 (NF105-CABO) · Neurofibroma, Plexiform
  16. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.
    Rogers CL, Won M, Vogelbaum MA, et al. · Int J Radiat Oncol Biol Phys · 2020 · Background
    PubMed: PMID 31786276 · NCT05425004 · Central Nervous System Neoplasms
  17. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32402160 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  18. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
    Chung HC, Ros W, Delord JP, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 30943124 · NCT04230954 · Adenocarcinoma

2019 (11 papers)

  1. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.
    Rabinowits G, Lezcano C, Catalano PJ, et al. · Oncologist · 2019 · Trial result
    PubMed: PMID 29445030 · NCT02036476 · Carcinoma, Merkel Cell
  2. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Matulonis UA, Sill MW, Makker V, et al. · Gynecol Oncol · 2019 · Derived
    PubMed: PMID 30587441 · NCT01716715 · Ovarian Neoplasms
  3. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
    Heller G, McCormack R, Kheoh T, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29272162 · NCT01605227 (COMET-1) · Prostatic Neoplasms
  4. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
    Escudier B, Powles T, Motzer RJ, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29309249 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  5. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
    Courtney KD, Infante JR, Lam ET, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29257710 · NCT02293980 · Carcinoma, Renal Cell
  6. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
    Choueiri TK, Hessel C, Halabi S, et al. · Eur J Cancer · 2019 · Derived
    PubMed: PMID 29550566 · NCT01835158 · Carcinoma, Renal Cell
  7. Reply to B. Rini et al and S. Buti et al.
    Choueiri TK, Halabi S, Morris MJ, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 28549224 · NCT01835158 · Carcinoma, Renal Cell
  8. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
    Cella D, Escudier B, Tannir NM, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29377755 · NCT01865747 (METEOR) · Carcinoma, Renal Cell
  9. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
    Wen PY, Drappatz J, de Groot J, et al. · Neuro Oncol · 2019 · Background
    PubMed: PMID 29016998 · NCT05425004 · Central Nervous System Neoplasms
  10. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
    Tannir NM, Pal SK, Atkins MB, et al. · Oncologist · 2019 · Background
    PubMed: PMID 29487224 · NCT05127824 · Carcinoma, Renal Cell
  11. Advances in meningioma genetics: novel therapeutic opportunities.
    Preusser M, Brastianos PK, Mawrin C, et al. · Nat Rev Neurol · 2019 · Background
    PubMed: PMID 29302064 · NCT05425004 · Central Nervous System Neoplasms

2018 (9 papers)

  1. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
    Zhen DB, Griffith KA, Ruch JM, et al. · Invest New Drugs · 2018 · Trial result
    PubMed: PMID 27439894 · NCT01663272 · Neoplasms
  2. miR-206-3p Inhibits 3T3-L1 Cell Adipogenesis via the c-Met/PI3K/Akt Pathway.
    Tang R, Ma F, Li W, et al. · Int J Mol Sci · 2018 · Trial result
    PubMed: PMID 28708070 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  3. Body composition by DXA.
    Shepherd JA, Ng BK, Sommer MJ, et al. · Bone · 2018 · Trial result
    PubMed: PMID 28625918 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  4. Obesity is a concern for bone health with aging.
    Shapses SA, Pop LC, Wang Y, et al. · Nutr Res · 2018 · Trial result
    PubMed: PMID 28385284 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  5. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A, Sonpavde G, Lo Vullo S, et al. · Eur Urol · 2018 · Trial result
    PubMed: PMID 27726966 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  6. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB, Sangro B, Yau T, et al. · Lancet · 2018 · Derived
    PubMed: PMID 28434648 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  7. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK, Meyer T, Cheng AL, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29972759 · NCT01908426 (CELESTIAL) · Carcinoma, Hepatocellular
  8. Economics of Malignant Gliomas: A Critical Review.
    Raizer JJ, Fitzner KA, Jacobs DI, et al. · J Oncol Pract · 2018 · Background
    PubMed: PMID 25466707 · NCT05425004 · Central Nervous System Neoplasms
  9. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M, Finn RS, Qin S, et al. · Lancet · 2018 · Background
    PubMed: PMID 29433850 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular

2017 (21 papers)

  1. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
    Zehir A, Benayed R, Shah RH, et al. · Nat Med · 2017 · Trial result
    PubMed: PMID 28481359 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
    Vergote IB, Smith DC, Berger R, et al. · Eur J Cancer · 2017 · Trial result
    PubMed: PMID 28755607 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  3. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Smith M, De Bono J, Sternberg C, et al. · J Clin Oncol · 2017 · Trial result
    PubMed: PMID 27400947 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  4. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
    Seymour L, Bogaerts J, Perrone A, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 28271869 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  5. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T, O'Donnell PH, Massard C, et al. · JAMA Oncol · 2017 · Trial result
    PubMed: PMID 28817753 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  6. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Necchi A, Pond GR, Raggi D, et al. · Clin Genitourin Cancer · 2017 · Trial result
    PubMed: PMID 27324051 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  7. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    Massard C, Gordon MS, Sharma S, et al. · J Clin Oncol · 2017 · Trial result
    PubMed: PMID 27269937 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  8. Bladder cancer.
    Kamat AM, Hahn NM, Efstathiou JA, et al. · Lancet · 2017 · Trial result
    PubMed: PMID 27345655 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  9. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R, Hall R, Kunk PR, et al. · Immunotherapy · 2017 · Trial result
    PubMed: PMID 27140411 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  10. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Drilon A, Rekhtman N, Arcila M, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27825636 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  11. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK, Halabi S, Sanford BL, et al. · J Clin Oncol · 2017 · Trial result
    PubMed: PMID 28199818 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  12. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK, Escudier B, Powles T, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27279544 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  13. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME, de Souza JA, Geyer S, et al. · J Clin Oncol · 2017 · Trial result
    PubMed: PMID 28817373 · NCT01811212 · Thyroid Neoplasms
  14. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM, Nechushtan H, Ron IG, et al. · Breast Cancer Res Treat · 2017 · Derived
    PubMed: PMID 27714541 · NCT00940225 · Carcinoma, Hepatocellular
  15. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
    Schöffski P, Gordon M, Smith DC, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 29059635 · NCT00940225 · Carcinoma, Hepatocellular
  16. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Neal JW, Dahlberg SE, Wakelee HA, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27825638 · NCT01708954 · Carcinoma, Non-Small-Cell Lung
  17. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
    Kelley RK, Verslype C, Cohn AL, et al. · Ann Oncol · 2017 · Derived
    PubMed: PMID 28426123 · NCT00940225 · Carcinoma, Hepatocellular
  18. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L, Zheng H, Yurgelun MB, et al. · Cancer · 2017 · Derived
    PubMed: PMID 28192597 · NCT01954745 · Bile Duct Neoplasms
  19. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
    Shih KC, Chowdhary S, Rosenblatt P, et al. · J Neurooncol · 2017 · Background
    PubMed: PMID 27311730 · NCT05425004 · Central Nervous System Neoplasms
  20. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
    Iacovelli R, Nolè F, Verri E, et al. · Target Oncol · 2017 · Background
    PubMed: PMID 26429561 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  21. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M, Steffens S, Bellut M, et al. · Med Oncol · 2017 · Background
    PubMed: PMID 27317388 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell

2016 (15 papers)

  1. Therapeutic uses of somatostatin and its analogues: Current view and potential applications.
    Rai U, Thrimawithana TR, Valery C, et al. · Pharmacol Ther · 2016 · Trial result
    PubMed: PMID 25956467 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  2. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
    Raggi D, Miceli R, Sonpavde G, et al. · Ann Oncol · 2016 · Trial result
    PubMed: PMID 26487582 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
    Michels S, Scheel AH, Scheffler M, et al. · J Thorac Oncol · 2016 · Trial result
    PubMed: PMID 26762747 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  4. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Masters GA, Temin S, Azzoli CG, et al. · J Clin Oncol · 2016 · Trial result
    PubMed: PMID 26324367 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  5. Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS).
    Di Gregorio S, Del Rio L, Rodriguez-Tolra J, et al. · Bone · 2016 · Trial result
    PubMed: PMID 25571842 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  6. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
    Wu H, Shih JY, Yang JC, et al. · J Thorac Oncol · 2016 · Derived
    PubMed: PMID 26291023 · NCT01639508 · Carcinoma, Non-Small-Cell Lung
  7. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
    Leibowitz-Amit R, Pintilie M, Khoja L, et al. · J Transl Med · 2016 · Derived
    PubMed: PMID 26762579 · NCT00940225 · Carcinoma, Hepatocellular
  8. Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.
    Folio LR, Turkbey EB, Steinberg SM, et al. · Eur J Radiol · 2016 · Derived
    PubMed: PMID 26149529 · NCT01688999 · Kidney Neoplasms
  9. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ, Jeon YK, Kim PJ, et al. · Ann Surg Oncol · 2016 · Background
    PubMed: PMID 26464193 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  10. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
    Schiefer AI, Mesteri I, Berghoff AS, et al. · Histopathology · 2016 · Background
    PubMed: PMID 25847631 · NCT03149822 · Carcinoma, Renal Cell
  11. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM, Fuentes-Mattei E, Wu W, et al. · Cancer Res · 2016 · Background
    PubMed: PMID 26282167 · NCT03612232 (CaboACC) · Adrenocortical Carcinoma
  12. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
    Leite KR, Reis ST, Junior JP, et al. · Diagn Pathol · 2016 · Background
    PubMed: PMID 26470780 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  13. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
    Hato T, Zhu AX, Duda DG, et al. · Immunotherapy · 2016 · Background
    PubMed: PMID 26865127 · NCT03149822 · Carcinoma, Renal Cell
  14. Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.
    Grimm SA, Chamberlain MC · CNS Oncol · 2016 · Background
    PubMed: PMID 26509217 · NCT05425004 · Central Nervous System Neoplasms
  15. A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma.
    Foxx-Lupo WT, Sing S, Alwan L, et al. · Clin Genitourin Cancer · 2016 · Background
    PubMed: PMID 26549824 · NCT05425004 · Central Nervous System Neoplasms

2015 (21 papers)

  1. Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD.
    Shepherd JA, Schousboe JT, Broy SB, et al. · J Clin Densitom · 2015 · Trial result
    PubMed: PMID 26277847 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C, Günther B, Popp AW, et al. · Osteoporos Int · 2015 · Trial result
    PubMed: PMID 24760244 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  3. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
    Reardon ZD, Patel SG, Zaid HB, et al. · Eur Urol · 2015 · Trial result
    PubMed: PMID 24472710 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Powles T, Eder JP, Fine GD, et al. · Nature · 2015 · Trial result
    PubMed: PMID 25428503 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  5. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.
    Plaza-Menacho I, Mologni L, McDonald NQ, et al. · Cell Signal · 2015 · Trial result
    PubMed: PMID 24705026 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  6. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
    Mukhopadhyay S, Pennell NA, Ali SM, et al. · J Thorac Oncol · 2015 · Trial result
    PubMed: PMID 25436805 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  7. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T, Tsukaguchi T, Satoh Y, et al. · Mol Cancer Ther · 2015 · Trial result
    PubMed: PMID 25349307 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  8. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK, Escudier B, Powles T, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26406150 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  9. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
    Zuo RC, Apolo AB, DiGiovanna JJ, et al. · JAMA Dermatol · 2015 · Derived
    PubMed: PMID 25427282 · NCT01688999 · Kidney Neoplasms
  10. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
    Smith MR, Sweeney CJ, Corn PG, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25225437 · NCT00940225 · Carcinoma, Hepatocellular
  11. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
    Basch E, Autio KA, Smith MR, et al. · Eur Urol · 2015 · Derived
    PubMed: PMID 24631409 · NCT00940225 · Carcinoma, Hepatocellular
  12. Expression of c-MET in Invasive Meningioma.
    Yun S, Koh JM, Lee KS, et al. · J Pathol Transl Med · 2015 · Background
    PubMed: PMID 25812657 · NCT05425004 · Central Nervous System Neoplasms
  13. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
    Voron T, Colussi O, Marcheteau E, et al. · J Exp Med · 2015 · Background
    PubMed: PMID 25601652 · NCT03149822 · Carcinoma, Renal Cell
  14. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Taube JM, Klein A, Brahmer JR, et al. · Clin Cancer Res · 2015 · Background
    PubMed: PMID 24714771 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  15. New agents and new targets for renal cell carcinoma.
    Philips GK, Atkins MB · Am Soc Clin Oncol Educ Book · 2015 · Background
    PubMed: PMID 24857106 · NCT03149822 · Carcinoma, Renal Cell
  16. Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
    Mukai S, Yorita K, Kawagoe Y, et al. · Hum Cell · 2015 · Background
    PubMed: PMID 25186085 · NCT03149822 · Carcinoma, Renal Cell
  17. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    Motzer RJ, Escudier B, McDermott DF, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26406148 · NCT03149822 · Carcinoma, Renal Cell
  18. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F, Santoni M, Ciccarese C, et al. · Cancer Treat Rev · 2015 · Background
    PubMed: PMID 25586601 · NCT03149822 · Carcinoma, Renal Cell
  19. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ, Wen P, Schiff D, et al. · Neuro Oncol · 2015 · Background
    PubMed: PMID 25100872 · NCT05425004 · Central Nervous System Neoplasms
  20. A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
    Choueiri TK, Pal SK, McDermott DF, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 24827131 · NCT03149822 · Carcinoma, Renal Cell
  21. PD-L1 expression in nonclear-cell renal cell carcinoma.
    Choueiri TK, Fay AP, Gray KP, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 25193987 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell

2014 (14 papers)

  1. Therapy monitoring of skeletal metastases with whole-body diffusion MRI.
    Padhani AR, Makris A, Gall P, et al. · J Magn Reson Imaging · 2014 · Trial result
    PubMed: PMID 24510426 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Bone biology and anabolic therapies for bone: current status and future prospects.
    Martin TJ · J Bone Metab · 2014 · Trial result
    PubMed: PMID 24707463 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  3. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
    Lee RJ, Saylor PJ, Michaelson MD, et al. · Clin Cancer Res · 2014 · Trial result
    PubMed: PMID 23553848 · NCT01347788 · Prostatic Neoplasms
  4. Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challenge.
    Huang W, Li X, Chen Y, et al. · Transl Oncol · 2014 · Trial result
    PubMed: PMID 24772219 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  5. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
    Drilon A, Wang L, Hasanovic A, et al. · Cancer Discov · 2014 · Trial result
    PubMed: PMID 23533264 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  6. Somatostatin analogs: does pharmacology impact antitumor efficacy?
    Chalabi M, Duluc C, Caron P, et al. · Trends Endocrinol Metab · 2014 · Trial result
    PubMed: PMID 24405892 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  7. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME, Pavel M, Ćwikła JB, et al. · N Engl J Med · 2014 · Trial result
    PubMed: PMID 25014687 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  8. Comprehensive molecular characterization of urothelial bladder carcinoma.
    Cancer Genome Atlas Research Network · Nature · 2014 · Trial result
    PubMed: PMID 24476821 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  9. Treatment of collecting duct carcinoma: current status and future perspectives.
    Procopio G, Testa I, Iacovelli R, et al. · Anticancer Res · 2014 · Background
    PubMed: PMID 24511050 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  10. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
    Pécuchet N, Bigot F, Gachet J, et al. · Ann Oncol · 2014 · Background
    PubMed: PMID 24190963 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  11. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.
    Li D, Han Z, Liu J, et al. · Med Oncol · 2014 · Background
    PubMed: PMID 23999841 · NCT03943602 (CaboPen)
  12. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC, Choueiri TK · Cancer J · 2014 · Background
    PubMed: PMID 23867513 · NCT03149822 · Carcinoma, Renal Cell
  13. Potential of new therapies like anti-PD1 in kidney cancer.
    Gunturi A, McDermott DF · Curr Treat Options Oncol · 2014 · Background
    PubMed: PMID 24504486 · NCT03149822 · Carcinoma, Renal Cell
  14. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
    Chevreau C, Ravaud A, Escudier B, et al. · Clin Genitourin Cancer · 2014 · Background
    PubMed: PMID 24268852 · NCT05425004 · Central Nervous System Neoplasms

2013 (11 papers)

  1. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
    Wang R, Hu H, Pan Y, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 23150706 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  2. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Lawrence MS, Stojanov P, Polak P, et al. · Nature · 2013 · Trial result
    PubMed: PMID 23770567 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
    Gautschi O, Zander T, Keller FA, et al. · J Thorac Oncol · 2013 · Trial result
    PubMed: PMID 23584301 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  4. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
    Smith DC, Smith MR, Sweeney C, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23169517 · NCT00940225 · Carcinoma, Hepatocellular
  5. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
    Yang W, Song Y, Lu YL, et al. · Immunology · 2013 · Background
    PubMed: PMID 23521696 · NCT04230954 · Adenocarcinoma
  6. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
    Walter S, Weinschenk T, Stenzl A, et al. · Nat Med · 2013 · Background
    PubMed: PMID 22842478 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  7. Modulation of immunity by antiangiogenic molecules in cancer.
    Terme M, Colussi O, Marcheteau E, et al. · Clin Dev Immunol · 2013 · Background
    PubMed: PMID 23320019 · NCT03149822 · Carcinoma, Renal Cell
  8. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
    Sennino B, Ishiguro-Oonuma T, Wei Y, et al. · Cancer Discov · 2013 · Background
    PubMed: PMID 22585997 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  9. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A, Rimassa L, Borbath I, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23182627 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  10. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
    Gibney GT, Aziz SA, Camp RL, et al. · Ann Oncol · 2013 · Background
    PubMed: PMID 23022995 · NCT03149822 · Carcinoma, Renal Cell
  11. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
    Di Lorenzo G, Buonerba C, Federico P, et al. · BJU Int · 2013 · Background
    PubMed: PMID 22958571 · NCT03943602 (CaboPen)

2012 (12 papers)

  1. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K, Soda M, Togashi Y, et al. · Nat Med · 2012 · Trial result
    PubMed: PMID 22327623 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  2. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    Lipson D, Capelletti M, Yelensky R, et al. · Nat Med · 2012 · Trial result
    PubMed: PMID 22327622 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  3. KIF5B-RET fusions in lung adenocarcinoma.
    Kohno T, Ichikawa H, Totoki Y, et al. · Nat Med · 2012 · Trial result
    PubMed: PMID 22327624 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  4. Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls.
    Koh DM, Blackledge M, Padhani AR, et al. · AJR Am J Roentgenol · 2012 · Trial result
    PubMed: PMID 22826385 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  5. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
    You H, Ding W, Dang H, et al. · Hepatology · 2012 · Background
    PubMed: PMID 21618573 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  6. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM, Chen J, Tan J, et al. · Mol Cancer Ther · 2012 · Background
    PubMed: PMID 21926191 · NCT04230954 · Adenocarcinoma
  7. Cancer statistics, 2012.
    Siegel R, Naishadham D, Jemal A, et al. · CA Cancer J Clin · 2012 · Background
    PubMed: PMID 22237781 · NCT03943602 (CaboPen)
  8. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
    Procopio G, Verzoni E, Iacovelli R, et al. · Clin Exp Nephrol · 2012 · Background
    PubMed: PMID 22278601 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  9. Targeting MET in cancer: rationale and progress.
    Gherardi E, Birchmeier W, Birchmeier C, et al. · Nat Rev Cancer · 2012 · Background
    PubMed: PMID 22270953 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  10. Coordinated regulation of myeloid cells by tumours.
    Gabrilovich DI, Ostrand-Rosenberg S, Bronte V, et al. · Nat Rev Immunol · 2012 · Background
    PubMed: PMID 22437938 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  11. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
    Di Lorenzo G, Federico P, Buonerba C, et al. · Eur Urol · 2012 · Background
    PubMed: PMID 21871710 · NCT03943602 (CaboPen)
  12. Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men.
    Backes DM, Bleeker MC, Meijer CJ, et al. · Int J Cancer · 2012 · Background
    PubMed: PMID 21618520 · NCT03943602 (CaboPen)

2011 (15 papers)

  1. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.
    Shiozawa Y, Pedersen EA, Havens AM, et al. · J Clin Invest · 2011 · Trial result
    PubMed: PMID 21436587 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E, Dahan L, Raoul JL, et al. · N Engl J Med · 2011 · Trial result
    PubMed: PMID 21306237 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  3. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R, Sherman SI, Ball DW, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21606412 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  4. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
    Galsky MD, Hahn NM, Rosenberg J, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21555688 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  5. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
    Ferlay J, Shin HR, Bray F, et al. · Int J Cancer · 2011 · Trial result
    PubMed: PMID 21351269 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  6. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
    Zhu Y, Li H, Yao XD, et al. · Urol Int · 2011 · Background
    PubMed: PMID 20980789 · NCT03943602 (CaboPen)
  7. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
    You WK, Sennino B, Williamson CW, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21613405 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  8. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Tartour E, Pere H, Maillere B, et al. · Cancer Metastasis Rev · 2011 · Background
    PubMed: PMID 21249423 · NCT03149822 · Carcinoma, Renal Cell
  9. EAU penile cancer guidelines 2009.
    Pizzocaro G, Algaba F, Horenblas S, et al. · Eur Urol · 2011 · Background
    PubMed: PMID 20163910 · NCT03943602 (CaboPen)
  10. Dynamic sentinel node biopsy for inguinal lymph node staging in patients with penile cancer: a systematic review and cumulative analysis of the literature.
    Neto AS, Tobias-Machado M, Ficarra V, et al. · Ann Surg Oncol · 2011 · Background
    PubMed: PMID 21308487 · NCT03943602 (CaboPen)
  11. Penile carcinogenesis in a low-incidence area: a clinicopathologic and molecular analysis of 115 invasive carcinomas with special emphasis on chronic inflammatory skin diseases.
    Mannweiler S, Sygulla S, Beham-Schmid C, et al. · Am J Surg Pathol · 2011 · Background
    PubMed: PMID 21681144 · NCT03943602 (CaboPen)
  12. 18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.
    Graafland NM, Valdés Olmos RA, Teertstra HJ, et al. · Eur J Nucl Med Mol Imaging · 2011 · Background
    PubMed: PMID 20349185 · NCT03943602 (CaboPen)
  13. Nodal staging in penile carcinoma by dynamic sentinel node biopsy after previous therapeutic primary tumour resection.
    Graafland NM, Valdés Olmos RA, Meinhardt W, et al. · Eur Urol · 2011 · Background
    PubMed: PMID 20633981 · NCT03943602 (CaboPen)
  14. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.
    Carmeliet P, Jain RK · Nat Rev Drug Discov · 2011 · Background
    PubMed: PMID 21629292 · NCT03149822 · Carcinoma, Renal Cell
  15. Human papillomavirus vaccination in males: the state of the science.
    Barroso LF, Wilkin T · Curr Infect Dis Rep · 2011 · Background
    PubMed: PMID 21365381 · NCT03943602 (CaboPen)

2010 (9 papers)

  1. Chemotherapy for penile and urethral carcinoma.
    Trabulsi EJ, Hoffman-Censits J · Urol Clin North Am · 2010 · Background
    PubMed: PMID 20674701 · NCT03943602 (CaboPen)
  2. [The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics].
    Protzel C, Ruppin S, Milerski S, et al. · Urologe A · 2010 · Background
    PubMed: PMID 19774356 · NCT03943602 (CaboPen)
  3. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer.
    Pettaway CA, Pagliaro L, Theodore C, et al. · Urology · 2010 · Background
    PubMed: PMID 20691886 · NCT03943602 (CaboPen)
  4. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Pagliaro LC, Williams DL, Daliani D, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20625118 · NCT03943602 (CaboPen)
  5. Human papillomavirus prevalence and type distribution in penile carcinoma.
    Miralles-Guri C, Bruni L, Cubilla AL, et al. · J Clin Pathol · 2010 · Background
    PubMed: PMID 19706632 · NCT03943602 (CaboPen)
  6. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy.
    Marconnet L, Rigaud J, Bouchot O, et al. · J Urol · 2010 · Background
    PubMed: PMID 20399455 · NCT03943602 (CaboPen)
  7. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
    Karim R, Jordanova ES, Piersma SJ, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 19825956 · NCT04230954 · Adenocarcinoma
  8. Cancer statistics, 2010.
    Jemal A, Siegel R, Xu J, et al. · CA Cancer J Clin · 2010 · Background
    PubMed: PMID 20610543 · NCT01683994 · Prostatic Neoplasms
  9. Management of the lymph nodes in penile cancer.
    Heyns CF, Fleshner N, Sangar V, et al. · Urology · 2010 · Background
    PubMed: PMID 20691885 · NCT03943602 (CaboPen)

2009 (12 papers)

  1. MR imaging of bone metastases and choice of sequence: spin echo, in-phase gradient echo, diffusion, and contrast medium.
    Vanel D, Casadei R, Alberghini M, et al. · Semin Musculoskelet Radiol · 2009 · Trial result
    PubMed: PMID 19455472 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Whole-body MRI for the staging and follow-up of patients with metastasis.
    Schmidt GP, Reiser MF, Baur-Melnyk A, et al. · Eur J Radiol · 2009 · Trial result
    PubMed: PMID 19457631 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Trial result
    PubMed: PMID 19097774 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. Lymphadenectomy in the surgical management of penile cancer.
    Protzel C, Alcaraz A, Horenblas S, et al. · Eur Urol · 2009 · Background
    PubMed: PMID 19264390 · NCT03943602 (CaboPen)
  5. Cisplatin and gemcitabine in the management of metastatic penile cancer.
    Power DG, Galvin DJ, Cuffe S, et al. · Urol Oncol · 2009 · Background
    PubMed: PMID 18367122 · NCT03943602 (CaboPen)
  6. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results.
    Pizzocaro G, Nicolai N, Milani A, et al. · Eur Urol · 2009 · Background
    PubMed: PMID 18649992 · NCT03943602 (CaboPen)
  7. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Ko JS, Zea AH, Rini BI, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19276286 · NCT03149822 · Carcinoma, Renal Cell
  8. Cancer statistics, 2009.
    Jemal A, Siegel R, Ward E, et al. · CA Cancer J Clin · 2009 · Background
    PubMed: PMID 19474385 · NCT01688999 · Kidney Neoplasms
  9. Molecular therapy for the treatment of hepatocellular carcinoma.
    Greten TF, Korangy F, Manns MP, et al. · Br J Cancer · 2009 · Background
    PubMed: PMID 19018262 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  10. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL, Kang YK, Chen Z, et al. · Lancet Oncol · 2009 · Background
    PubMed: PMID 19095497 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  11. Penile cancer: epidemiology, pathogenesis and prevention.
    Bleeker MC, Heideman DA, Snijders PJ, et al. · World J Urol · 2009 · Background
    PubMed: PMID 18607597 · NCT03943602 (CaboPen)
  12. Systematic review of human papillomavirus prevalence in invasive penile cancer.
    Backes DM, Kurman RJ, Pimenta JM, et al. · Cancer Causes Control · 2009 · Background
    PubMed: PMID 19082746 · NCT03943602 (CaboPen)

2008 (12 papers)

  1. Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells.
    Perdomo G, Martinez-Brocca MA, Bhatt BA, et al. · J Biol Chem · 2008 · Trial result
    PubMed: PMID 18362143 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Dixon techniques for water and fat imaging.
    Ma J · J Magn Reson Imaging · 2008 · Trial result
    PubMed: PMID 18777528 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  3. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.
    Herr HW, Morales A · J Urol · 2008 · Trial result
    PubMed: PMID 17997439 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1.
    Azar R, Najib S, Lahlou H, et al. · Cell Mol Life Sci · 2008 · Trial result
    PubMed: PMID 18810319 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  5. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
    Theodore C, Skoneczna I, Bodrogi I, et al. · Ann Oncol · 2008 · Background
    PubMed: PMID 18417462 · NCT03943602 (CaboPen)
  6. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    Scher HI, Halabi S, Tannock I, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18309951 · NCT01683994 · Prostatic Neoplasms
  7. Management of penile cancer.
    Ornellas AA · J Surg Oncol · 2008 · Background
    PubMed: PMID 17918225 · NCT03943602 (CaboPen)
  8. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience.
    Ornellas AA, Kinchin EW, Nóbrega BL, et al. · J Surg Oncol · 2008 · Background
    PubMed: PMID 18425779 · NCT03943602 (CaboPen)
  9. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML, Jaeger E, Shi Y, et al. · Clin Cancer Res · 2008 · Background
    PubMed: PMID 18676741 · NCT03149822 · Carcinoma, Renal Cell
  10. Expression and mutational analysis of MET in human solid cancers.
    Ma PC, Tretiakova MS, MacKinnon AC, et al. · Genes Chromosomes Cancer · 2008 · Background
    PubMed: PMID 18709663 · NCT05425004 · Central Nervous System Neoplasms
  11. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM, Ricci S, Mazzaferro V, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18650514 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  12. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients.
    Leijte JA, Kirrander P, Antonini N, et al. · Eur Urol · 2008 · Background
    PubMed: PMID 18440124 · NCT03943602 (CaboPen)

2007 (13 papers)

  1. Cancer phenomics: RET and PTEN as illustrative models.
    Zbuk KM, Eng C · Nat Rev Cancer · 2007 · Trial result
    PubMed: PMID 17167516 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  2. Rationale for the use of somatostatin analogs as antitumor agents.
    Susini C, Buscail L · Ann Oncol · 2007 · Trial result
    PubMed: PMID 16801334 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  3. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB, Remenar E, van Herpen C, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 17960012 · NCT03943602 (CaboPen)
  4. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation.
    Spiess PE, Izawa JI, Bassett R, et al. · J Urol · 2007 · Background
    PubMed: PMID 17509308 · NCT03943602 (CaboPen)
  5. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR, Hershock DM, Blajman CR, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 17960013 · NCT03943602 (CaboPen)
  6. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
    Oudard S, Banu E, Vieillefond A, et al. · J Urol · 2007 · Background
    PubMed: PMID 17437788 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  7. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival.
    Lont AP, Kroon BK, Gallee MP, et al. · J Urol · 2007 · Background
    PubMed: PMID 17296384 · NCT03943602 (CaboPen)
  8. Neoadjuvant chemotherapy in advanced penile carcinoma.
    Leijte JA, Kerst JM, Bais E, et al. · Eur Urol · 2007 · Background
    PubMed: PMID 17316964 · NCT03943602 (CaboPen)
  9. Lymphoscintigraphy in penile cancer: limited value of sentinel node biopsy in patients with clinically suspicious lymph nodes.
    Hungerhuber E, Schlenker B, Frimberger D, et al. · World J Urol · 2007 · Background
    PubMed: PMID 16688459 · NCT03943602 (CaboPen)
  10. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma.
    Heideman DA, Waterboer T, Pawlita M, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17925550 · NCT03943602 (CaboPen)
  11. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma.
    Hakenberg OW, Nippgen JB, Froehner M, et al. · BJU Int · 2007 · Background
    PubMed: PMID 17125480 · NCT03943602 (CaboPen)
  12. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.
    Bermejo C, Busby JE, Spiess PE, et al. · J Urol · 2007 · Background
    PubMed: PMID 17382727 · NCT03943602 (CaboPen)
  13. Incidence trends in primary malignant penile cancer.
    Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, et al. · Urol Oncol · 2007 · Background
    PubMed: PMID 17826651 · NCT03943602 (CaboPen)

2006 (6 papers)

  1. Mechanisms of disease: is osteoporosis the obesity of bone?
    Rosen CJ, Bouxsein ML · Nat Clin Pract Rheumatol · 2006 · Trial result
    PubMed: PMID 16932650 · NCT05265988 (MERIDIAN) · Prostatic Neoplasms
  2. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A, Galsky MD, Vickers AJ, et al. · Cancer · 2006 · Trial result
    PubMed: PMID 16773629 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. Edmonton symptom assessment scale: Italian validation in two palliative care settings.
    Moro C, Brunelli C, Miccinesi G, et al. · Support Care Cancer · 2006 · Background
    PubMed: PMID 15937688 · NCT03943602 (CaboPen)
  4. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
    Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, et al. · J Clin Invest · 2006 · Background
    PubMed: PMID 16710476 · NCT06535737 (CPAB) · Carcinoma, Hepatocellular
  5. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R, López-Pousa A, Martínez-Trufero J, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16275937 · NCT03943602 (CaboPen)
  6. Trends in cancer risk among people with AIDS in the United States 1980-2002.
    Engels EA, Pfeiffer RM, Goedert JJ, et al. · AIDS · 2006 · Background
    PubMed: PMID 16868446 · NCT03943602 (CaboPen)

2005 (5 papers)

  1. Novel modalities of somatostatin actions.
    Krantic S, Goddard I, Saveanu A, et al. · Eur J Endocrinol · 2005 · Trial result
    PubMed: PMID 15588232 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  2. Extended lymphadenectomy in penile cancer.
    Pompeo AC · Can J Urol · 2005 · Background
    PubMed: PMID 15780162 · NCT03943602 (CaboPen)
  3. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases.
    Kroon BK, Horenblas S, Lont AP, et al. · J Urol · 2005 · Background
    PubMed: PMID 15711276 · NCT03943602 (CaboPen)
  4. Sentinel lymph node biopsy in penile cancer: evolution and insights.
    Izawa J, Kedar D, Wong F, et al. · Can J Urol · 2005 · Background
    PubMed: PMID 15780161 · NCT03943602 (CaboPen)
  5. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease.
    Daling JR, Madeleine MM, Johnson LG, et al. · Int J Cancer · 2005 · Background
    PubMed: PMID 15825185 · NCT03943602 (CaboPen)

2004 (2 papers)

  1. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP, Tangen CM, Hussain MH, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15470214 · NCT01683994 · Prostatic Neoplasms
  2. Penile carcinoma: a challenge for the developing world.
    Misra S, Chaturvedi A, Misra NC, et al. · Lancet Oncol · 2004 · Background
    PubMed: PMID 15050955 · NCT03943602 (CaboPen)

2003 (2 papers)

  1. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity.
    Pola S, Cattaneo MG, Vicentini LM, et al. · J Biol Chem · 2003 · Trial result
    PubMed: PMID 12902325 · NCT04427787 (LOLA) · Neuroendocrine Tumors
  2. Advanced penile carcinoma.
    Culkin DJ, Beer TM · J Urol · 2003 · Background
    PubMed: PMID 12853775 · NCT03943602 (CaboPen)

2002 (2 papers)

  1. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
    Vaughn DJ, Broome CM, Hussain M, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 11844814 · NCT01688999 · Kidney Neoplasms
  2. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners.
    Castellsagué X, Bosch FX, Muñoz N, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 11948269 · NCT03943602 (CaboPen)

2001 (3 papers)

  1. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis.
    Rubin MA, Kleter B, Zhou M, et al. · Am J Pathol · 2001 · Background
    PubMed: PMID 11583947 · NCT03943602 (CaboPen)
  2. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group.
    Coindre JM, Terrier P, Guillou L, et al. · Cancer · 2001 · Background
    PubMed: PMID 11346874 · NCT01755195 · Sarcoma
  3. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
    Bezerra AL, Lopes A, Santiago GH, et al. · Cancer · 2001 · Background
    PubMed: PMID 11413520 · NCT03943602 (CaboPen)

2000 (1 paper)

  1. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
    Young H, Baum R, Cremerius U, et al. · Eur J Cancer · 2000 · Trial result
    PubMed: PMID 10673991 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms

1999 (2 papers)

  1. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.
    Perry A, Scheithauer BW, Stafford SL, et al. · Cancer · 1999 · Background
    PubMed: PMID 10223247 · NCT05425004 · Central Nervous System Neoplasms
  2. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.
    Haas GP, Blumenstein BA, Gagliano RG, et al. · J Urol · 1999 · Background
    PubMed: PMID 10332445 · NCT03943602 (CaboPen)

1998 (3 papers)

  1. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features.
    Bongarzone I, Vigneri P, Mariani L, et al. · Clin Cancer Res · 1998 · Trial result
    PubMed: PMID 9516975 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  2. Meningioma grading: an analysis of histologic parameters.
    Perry A, Stafford SL, Scheithauer BW, et al. · Am J Surg Pathol · 1998 · Background
    PubMed: PMID 9414189 · NCT05425004 · Central Nervous System Neoplasms
  3. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin.
    Corral DA, Sella A, Pettaway CA, et al. · J Urol · 1998 · Background
    PubMed: PMID 9783949 · NCT03943602 (CaboPen)

1997 (2 papers)

  1. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney.
    Selli C, Amorosi A, Vona G, et al. · J Urol · 1997 · Background
    PubMed: PMID 9186368 · NCT03354884 (BONSAI) · Carcinoma, Renal Cell
  2. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, et al. · J Clin Oncol · 1997 · Background
    PubMed: PMID 9164195 · NCT01688999 · Kidney Neoplasms

1996 (1 paper)

  1. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience.
    Pettaway CA, Pisters LL, Dinney CP, et al. · J Urol · 1996 · Background
    PubMed: PMID 7500444 · NCT03943602 (CaboPen)

1995 (1 paper)

  1. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma.
    Gregoire L, Cubilla AL, Reuter VE, et al. · J Natl Cancer Inst · 1995 · Background
    PubMed: PMID 7473819 · NCT03943602 (CaboPen)

1993 (1 paper)

  1. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Edmonson JH, Ryan LM, Blum RH, et al. · J Clin Oncol · 1993 · Background
    PubMed: PMID 8315424 · NCT01755195 · Sarcoma

1992 (1 paper)

  1. Cisplatin and 5-fluorouracil in advanced cancer of the penis.
    Shammas FV, Ous S, Fossa SD, et al. · J Urol · 1992 · Background
    PubMed: PMID 1538445 · NCT03943602 (CaboPen)

1991 (1 paper)

  1. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract.
    Dexeus FH, Logothetis CJ, Sella A, et al. · J Urol · 1991 · Background
    PubMed: PMID 1719241 · NCT03943602 (CaboPen)

1990 (2 papers)

  1. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
    Grieco M, Santoro M, Berlingieri MT, et al. · Cell · 1990 · Trial result
    PubMed: PMID 2406025 · NCT04131543 (CRETA) · Carcinoma, Non-Small-Cell Lung
  2. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
    Hussein AM, Benedetto P, Sridhar KS, et al. · Cancer · 1990 · Background
    PubMed: PMID 2297633 · NCT03943602 (CaboPen)

1989 (4 papers)

  1. Optimal two-stage designs for phase II clinical trials.
    Simon R · Control Clin Trials · 1989 · Background
    PubMed: PMID 2702835 · NCT03943602 (CaboPen)
  2. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.
    Pizzocaro G, Piva L · Acta Oncol · 1989 · Background
    PubMed: PMID 2466471 · NCT03943602 (CaboPen)
  3. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study.
    Gagliano RG, Blumenstein BA, Crawford ED, et al. · J Urol · 1989 · Background
    PubMed: PMID 2642312 · NCT03943602 (CaboPen)
  4. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A, Ryan L, Sulkes A, et al. · J Clin Oncol · 1989 · Background
    PubMed: PMID 2504890 · NCT01755195 · Sarcoma

1988 (1 paper)

  1. Penile cancer: is there an epidemiological role for smoking and sexual behaviour?
    Hellberg D, Valentin J, Eklund T, et al. · Br Med J (Clin Res Ed) · 1988 · Background
    PubMed: PMID 3120988 · NCT03943602 (CaboPen)

1986 (1 paper)

  1. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome.
    Jääskeläinen J, Haltia M, Servo A, et al. · Surg Neurol · 1986 · Background
    PubMed: PMID 3945904 · NCT05425004 · Central Nervous System Neoplasms

1983 (2 papers)

  1. Cold storage preservation of islet and pancreas grafts as assessed by in vivo function after transplantation to diabetic hosts.
    Sutherland DE, Morrow CE, Florack G, et al. · Cryobiology · 1983 · Background
    PubMed: PMID 6406150 · NCT03149822 · Carcinoma, Renal Cell
  2. Adjuvant treatment using bleomycin in squamous cell carcinoma of penis: study of 19 cases.
    Maiche AG · Br J Urol · 1983 · Background
    PubMed: PMID 6194844 · NCT03943602 (CaboPen)

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 14 May 2026 21:41:01 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).